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Hepatitis E virus (HEV) is the causative agent of hepatitis E, an acute form of viral hepatitis. The open reading frame 2 (ORF2) of HEV
encodes the viral capsid protein, which can self-oligomerize into virus-like particles. To understand the domains within this protein
important for capsid biogenesis,we have carried out in vitro analyses of association and folding patterns of wild type and mutant ORF2
proteins. When expressed in vitro or in transfected cells, the ORF2 protein assembled as dimers, trimers and higher order forms. While
N-terminal deletions up to 111 amino acids had no effect, the deletion of amino acids 585–610 led to reduced homo-oligomerization.
This deletion also resulted in aberrant folding of the protein, as determined by its sensitivity to trypsin. This study suggests that a
C-terminal hydrophobic region encompassing amino acids 585–610 of the ORF2 protein might be critical for capsid biogenesis.
INTRODUCTION
The hepatitis E virus (HEV) is endemic in many resource-
poor regions of the world, where it is responsible for large
epidemics and rampant sporadic cases of acute viral hepatitis
[1–4]. In developed countries, this disease is seen primarily in
travellers to areas of HEV endemicity. Though largely a self-
limited infection, it results in significant morbidity and mor-
tality, especially among pregnant women [5], in whom the
disease is exacerbated by the development of fulminant liver
disease. In sporadic acute hepatitis E, outside of pregnancy
as well, a fraction of patients develop fulminant disease with
high mortality [6]. The transmission of HEV is feco-oral, with
only human-to-human transfer recognized so far [7]. How-
ever, the recent discovery of a novel virus closely related to
HEV in domestic swine [8] suggests possible zoonotic reser-
voirs as well.
In the absence of an in vitro system for virus propaga-
tion, the biology of HEV remains poorly studied. The viral
genome has been cloned from multiple geographically dis-
tinct isolates and shows a high degree of sequence conserva-
tion [9–15]. The genome of HEV is a positive-stranded RNA
of about 7.5 kb with short 5’ and 3’ noncoding regions span-
ning a coding region that includes three open reading frames
(ORFs) [9]. The ORF1 encodes a putative nonstructural pro-
tein with domains for a viral methyltransferase, papain-like
cysteine protease, RNA helicase, and an RNA-dependent RNA
polymerase [16]. The ORF2 encodes the viral capsid protein
(pORF2), and ORF3 expresses a small protein of unknown
function (pORF3). Earlier we have shown that pORF3 is a
cytoskeleton-associated phosphoprotein, which appears to be
phosphorylated by the cellular mitogen-activated protein ki-
nase [17].
The ORF2 of HEV has been expressed using various sys-
tems, includingE. coli [14, 18], insect cells using baculoviruses
[19],and in animal cells using transfection [20],vaccinia virus
[21] and alphaviruses [22]. The expression studies in insect
cells have shown that pORF2 can form virus-like particles
(VLPs) that are secreted from infected cells [23]. Multiple
immunodominant B-cell epitopes have been identified on
pORF2 and the protein contains a highly basic N-terminal
half with about 10% arginine residues, presumably to neu-
tralize the negative charge on the RNA genome backbone.
These observations support the premise that ORF2 encodes
the HEV capsid protein. In earlier studies, we have observed
ORF2 to express approximately 74–88 kDa protein, one
form being N-glycosylated [20]. The glycosylation has been
mapped to asparagine residues at positions 137, 310, and
562 [24]. We have further shown that pORF2 carries an N-
terminal signal sequence that translocates it across the endo-
plasmic reticulum (ER) membrane; the ER also appears to be
the major site of pORF2 glycosylation and accumulation [24].
The structural protein of a simple virus such as HEV
should have the ability to self-assemble into a capsid
structure. In this work, we have explored the homo-
oligomerization potential of pORF2 using cell transfection,
in vitro expression and cross-linking experiments. The re-
sults reveal that homo-oligomerization of pORF2 depends
largely upon a hydrophobic region towards the C-terminus
of the protein.
MATERIALS AND METHODS
Vectors and mutagenesis
The expression vectors pSG-ORF2, pSG-ORF2[∆2–34]
and pSG-ORF2[137/310/562], expressing the wild type,
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Figure 1: The 660 amino acid protein (pORF2) encoded by the HEV ORF2 is shown schematically, with three major regions: the extreme
N-terminus, containing the putative signal sequence (open box), the highly basic N-terminal half of the protein (+) and a C-terminal
hydrophobic stretch (filled box). The positions of three potential N-linked glycosylation sites are shown at amino acid residues 137, 310,
562. The deletion mutants used in this study are also shown schematically.
signal sequence-deleted and glycosylation-null ORF2 pro-
teins, respectively, have been described earlier [9]. The
ORF2[∆2–111] mutant was generated by digesting ORF2 at a
SalI site (nucloetide 381), followed by oligonucleotide-based
reconstruction. The expression vectors pSG-ORF2[∆585–
610] and pSG-ORF2[∆2–111/∆585–610] were generated
by deleting a C-terminal hydrophobic region encompassing
amino acids 585–610 by site-directed mutgenesis Figure 1.
ORF2 expression
The transfection and labeling of cultured cells was car-
ried out essentially as described earlier [24]. For in vitro ex-
pression, a coupled transcription-translation system (TNT;
Promega, USA) was used. The reactions were quenched with
200µg/ml cycloheximide and 200µM methionine and the
mixture incubated further at 30◦C for 60 min to permit
oligomerization.
Cross-linking and gradient analysis
Cell lysates were prepared in 10 mM sodium phosphate,
pH 7.4 containing 100 mM NaCl, 1% Triton X-100 and a
cocktail of protease inhibitors (Invitrogen, USA). To 500µL
of cell lysate, 50µL of 10× cross-linking buffer (500 mM
Tris-HCl, pH 8.0, 1 M NaCl) and 13µL of 2% glutaralde-
hyde (final 0.05%) were added. Following incubation at
room temperature for 1 h, the cross-linking reactions were
quenched with 50µL of 10% SDS. For cross-linking of in
vitro translation reactions, 13µL of the reaction mixture was
diluted to 500µL with PBS, pH 7.4 and treated as above.
The lysates, either directly or after cross-linking, were lay-
ered on a 3.5 mL linear gradient of 5%–25% (w/v) su-
crose in PBS, pH 7.4 containing 0.1% Triton X-100. Fol-
lowing ultracentrifugation in a Beckman SW60 rotor for
20 h at 41,000 rpm and 4◦C, 0.5 mL fractions were col-
lected by puncturing the bottom of the tubes. Each frac-
tion was immunoprecipitated with anti-pORF2 antibodies,
subjected to electrophoresis on 3.5% or 7.5% nonreduc-
ing polyacrylamide gels and the proteins detected by flu-
orography. The 3.5% gels were prepared and run as de-
scribed [25].
Translocation assays and proteolytic analysis
The in vitro expression of wild type and mutant ORF2
proteins was carried out as described above, in the absence
or presence of microsomal membranes (Promega, USA), ac-
cording to the supplier’s protocol. Following protein synthe-
sis, the reactions were chilled on ice and membrane vesicles
were stabilized with 3 mM tetracaine and 10 mM CaCl2. The
reaction mixtures were each divided into three aliquots,which
were then treated on ice for 1 h as follows: (1) no addition,
(2) 250µg/mL trypsin, and (3) 250µg/mL trypsin and 0.7%
Triton X-100. The proteolysis was terminated by adding an
equal volume of boiling SDS-PAGE loading dye buffer to the
reaction mixture. The samples were boiled for 5 min and an-
alyzed on reducing SDS-7.5% polyacrylamide gels followed
by fluorography.
RESULTS
The ORF2 protein undergoes homo-oligomerization
To determine if pORF2 can oligomerize, COS-1 cells
were transiently transfected with vectors expressing wild type
ORF2 or the N-terminal deletion mutant ORF2[∆2–111].
After cross-linking and sucrose gradient sedimentation, the
distribution of ORF2 proteins across the gradient was de-
termined by immunoprecipitation of each fraction. Multi-
ple species ranging from monomers to trimers were evident
(Figure 2), showing that pORF2 has the ability to homo-
oligomerize. For wild type pORF2, very little monomeric
and some dimeric forms were evident; most of the protein
was seen as trimers or higher oligomers. On deletion of the
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Figure 2: COS-1 cells transfected with wild type or ∆2–111 ORF2 expression plasmids were lysed 48 hours post-transfection, the lysates
cross-linked with glutaraldehyde and separated on a sucrose gradient as described in materials and methods. The gradient fractions were
immunoprecipitated with anti-pORF2 antibodies and analyzed on nonreducing 3.5% polyacrylamide gels.
N-terminal 111 amino acids, the dimeric forms were signif-
icantly reduced. However, the trimers and higher oligomers
were still observed towards the bottom of the gradient. The
ORF2 protein oligomers were also analyzed after a 3 h chase
following the 30 min labeling period. Though the signals were
weaker, there was no change in the oligomer patterns follow-
ing the chase period. This suggested that pORF2 turnover
in cells was rapid and that oligomer formation took place
either cotranslationally or very soon following translation.
These results also indicated that up to 111 amino acids at the
N-terminus were dispensable for the homo-oligomerization
of pORF2.
In vitro homo-oligomerization of pORF2
To determine if the in vitro expressed pORF2 can
also oligomerize, the proteins were immunoprecipitated be-
fore or after cross-linking and analyzed on a nonreducing
3.5% gel (Figure 3). About 50% of the wild type ORF2 pro-
tein was found as dimers, with a small fraction as higher
oligomers as well. The deletion of 111 N-terminal amino
acids again showed no effect on this distribution. However,
the deletion of amino acids 585–610 resulted in a drastic loss
of pORF2 dimers. This effect was even more pronounced
in the ∆2–111/∆585–610 double mutant. The ∆2–34 and
137/310/562 mutants showed wild type patterns. To further
evaluate the complexes formed, sucrose gradient sedimenta-
tion of in vitro expressed wild type and mutant ORF2 proteins
was carried out (Figure 4). Following immunoprecipitation
and nonreducing SDS-PAGE, two predominant forms, cor-
responding to monomers and dimers, were again observed.
As expected, the proportion of dimers was higher in frac-
tions towards the bottom of the gradient. When compared
to the wild type protein, the ∆2–111 mutant being signifi-
cantly smaller, sedimented to a lower density in the gradient.
In agreement with earlier results, while the deletion of 111
N-terminal residues showed no effect on the monomer-to-
dimer ratio, the deletion of amino acids 585–610 resulted
in loss of the dimeric species. Taken together, these results
suggested that residues 585 to 610 were required for pORF2
oligomerization.
Sensitivity of pORF2 to proteolysis
Wild type and mutant ORF2 proteins were synthesized in
vitro, in the absence or presence of added microsomal mem-
branes and then subjected to trypsin digestion (Figure 5).
The wild type and ∆585–610 proteins, with an intact N-
terminus, were found to be protected from trypsin digestion
when synthesized in the presence of membranes (lanes 5–
7). The ∆2–111 and ∆2–111/∆585–610 mutant proteins,
lacking the N-terminus, were not protected under identical
conditions. Further, the trypsin protection was lost when the
membrane vesicles were lysed with detergent. These results
were in agreement with our earlier findings of a functional
membrane-translocating signal sequence at the N-terminus
of pORF2. In the absence of membranes, the wild type as
well as mutant proteins were susceptible to trypsin, but the
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Figure 3: In vitro synthesized pORF2 and mutant proteins were subjected to immunoprecipitation before (A) or after (B) cross-linking. The
mixtures were analyzed on a nonreducing 7.5% polyacrylamide gel. Molecular size markers are shown in kilodaltons (MW).
polypeptide patterns generated were vastly different (lanes
1–3). The wild type protein showed at least four promi-
nent polypeptides ranging in size from about 40–60 kDa. The
∆2–111 mutant showed two major polypeptides in the 50–
60 kDa size range. The ∆585–610 mutant protein, however,
was completely sensitive to trypsin, an effect seen with the
∆2–111/∆585–610 protein as well. These results suggested
that the region encompassing amino acids 585–610 also in-
fluenced the folding of pORF2.
DISCUSSION
Here we have analyzed the HEV capsid protein, pORF2,
by chemical cross-linking and sucrose gradient sedimentation
to show that the protein has the ability to homo-oligomerize.
These oligomers form shortly after synthesis of the polypep-
tides and their presence in specific fractions of the gradi-
ent, indicated that they were of discrete sizes. The assembly
of oligomers generally takes place post-translationally after
folding of the individual subunits, which require one or more
folded domains to have structurally defined surfaces for spe-
cific contacts. We have shown earlier that pORF2 is translo-
cated across the ER membrane by virtue of an N-terminal sig-
nal sequence [24]. The in vitro translation, translocation, and
trypsin sensitivity experiments reported here also supported
those observations. Further, analysis of pORF2 glycosylation
patterns in the presence of protein translocation inhibitors
such as Brefeldin A and Monensin suggested that ER was also
the major site of pORF2 accumulation [24].
It is tempting to speculate that oligomerization of pORF2
occurs inside the ER, in the intermediate compartment, or
during transit to the cis-Golgi. However, when expressed in
COS-1 cells, the ∆2–111 mutant, which lacks the ER translo-
cating signal sequence, did not show any difference in its
homo-oligomerization compared to the wild type protein.
Further, pORF2 expressed in vitro was also found to homo-
oligomerize. Though in both of these cases the ORF2 pro-
teins displayed oligomerization, the type of interactions may
be different. In the COS-1 cell-expressed protein, the major
oligomeric species was a trimer, while in the protein expressed
in vitro the predominant species was a dimer. Thus, while
pORF2 being a capsid protein, can spontaneously oligomer-
ize, the cellular compartment and its resident proteins are
likely to play a role in the formation of productive capsids.
The analysis of pORF2 mutants clearly showed that while
an N-terminal region as large as 111 amino acids was not
required for its homo-oligomerization, a C-terminal hy-
drophobic stretch encompassing amino acids 585–610 was
critical for it. When ORF2 was expressed in baculovirus-
infected insect cells, multiple forms of the protein were found
[19, 23, 26, 27]. In one study, a 50 kDa form secreted as virus-
like particles [23], had its N-terminus at amino acid 112
of ORF2. Similar observations were made by other workers
[26, 27], with one report placing the C-terminus of truncated
forms at amino acid residues 578 and 607 [26]. The trun-
cation of N-terminal 111 amino acids appeared to stabilize
the oligomeric structure of pORF2. Our results on trypsin
sensitivity, presented here, also support these observations.
Recently, the C-terminal region encompassing amino acids
578–607 has been shown to be critical for generating neu-
tralizing antibodies in experimentally infected chimpanzees
[28]. Interestingly, this is the same region we find to be im-
portant for capsid assembly.
The sensivity of wild type and mutant ORF2 proteins
has provided some clues about its folding. The ORF2 protein
has 58 possible trypsin digestion sites and complete digestion
with trypsin should theoretically release peptides in the range
of 174 to 5556 Da. However, the generation of 40–60 kDa
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Figure 4: Coupled transcription-translation reactions were carried out for the in vitro synthesis of wild type or mutant ORF2 proteins. The
reaction mixtures were separated on a sucrose gradient, the fractions immunoprecipitated and analyzed on nonreducing 7.5% polyacrylamide
gels. Molecular size markers are shown in kilodaltons.
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Figure 5: Wild type or mutant ORF2 proteins were synthesized in vitro in the absence (lanes 1–3) or presence (lanes 5–7) of canine pancreatic
membranes. Subsequently, each reaction mix was divided into three parts, treated with trypsin and Triton-X100 as shown and analyzed on
reducing SDS-7.5% polyacrylamide gels. Molecular size markers (lane 4) are, from top to bottom, 200 kDa, 97.4 kDa, 66 kDa, and 46 kDa.
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polypeptides on trypsin digestion of wild type or ∆2–111
mutant pORF2, suggested that a majority of trypsin sites were
buried in the folded protein and were therefore not accessible
to the protease. However, under identical reaction conditions,
the ∆585–610 and ∆2–111/∆585–610 mutants were com-
pletely sensitive to trypsin. This indicated that the 585–610
region, apart from its role in pORF2 oligomerization, was
also critical for proper folding of the protein. It is likely that
oligomerization depends upon proper folding of the protein.
We propose that the ORF2 protein has two distinct parts.
The positively charged N-terminal part is important for
RNA encapsidation, while the C-terminal part is required
for oligomerization into a basic structural unit. While these
in vitro studies do educate us about the nature of the HEV
capsid protein, the details of pORF2 processing in an HEV-
inefected cell and its role in capsid assembly remain to be
determined. Such studies will have to wait for the availability
of a viable in vitro culture system for HEV.
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